🇺🇸 FDA
Patent

US 10676469

Kappa opioid receptor antagonists and products and methods related thereto

granted A61PA61P25/00A61P25/06

Quick answer

US patent 10676469 (Kappa opioid receptor antagonists and products and methods related thereto) held by BLACKTHORN THERAPEUTICS, INC. expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BLACKTHORN THERAPEUTICS, INC.
Grant date
Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
59
CPC classes
A61P, A61P25/00, A61P25/06